Identification of immune cell infiltration pattern and related critical genes in metastatic castration-resistant prostate cancer by bioinformatics analysis

被引:7
|
作者
Fan, Caibin [1 ]
Lu, Wei [2 ]
Li, Kai [1 ]
Zhao, Chunchun [1 ]
Wang, Fei [1 ]
Ding, Guanxiong [3 ]
Wang, Jianqing [1 ]
机构
[1] Nanjing Med Univ, Affiliated Suzhou Hosp, Suzhou Municipal Hosp, Gusu Sch,Dept Urol, 26 Daoqian Rd, Suzhou 215000, Jiangsu, Peoples R China
[2] Suzhou Vocat Hlth Coll, Sch Nursing, Suzhou, Jiangsu, Peoples R China
[3] Fudan Univ, Huashan Hosp, Dept Urol, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
Immune infiltration; metastatic castration resistant prostate cancer (mCRPC); RNA sequencing; bioinformatics analysis; immunotherapy; DIFFERENTIAL EXPRESSION ANALYSIS; BREAST-CANCER; IMMUNOTHERAPY; SURVIVAL; INTERLEUKIN-2; PROLIFERATION; ENZALUTAMIDE; ANTAGONISTS; INHIBITION; DIAGNOSIS;
D O I
10.3233/CBM-203222
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) is the lethal stage of prostate cancer and the main cause of morbidity and mortality, which is also a potential target for immunotherapy. METHOD: In this study, using the Approximate Relative Subset of RNA Transcripts (CIBERSORT) online method, we analysed the immune cell abundance ratio of each sample in the mCRPC dataset. The EdgeR (an R package) was used to classify differentially expressed genes (DEGs). Using the Database for annotation, visualisation and interactive exploration (DAVID) online method, we performed functional enrichment analyses. STRING online database and Cytoscape tools have been used to analyse protein-protein interaction (PPI) and classify hub genes. RESULTS: The profiles of immune infiltration in mCRPC showed that Macrophages M2, Macrophages M0, T cells CD4 memory resting, T cells CD8 and Plasma cells were the main infiltration cell types in mCRPC samples. Macrophage M0 and T cell CD4 memory resting abundance ratios were correlated with clinical outcomes. We identified 1102 differentially expressed genes (DEGs) associated with the above two immune cells to further explore the underlying mechanisms. Enrichment analysis found that DEGs were substantially enriched in immune response, cell metastasis, and metabolism related categories. We identified 20 hub genes by the protein-protein interaction network analysis. Further analysis showed that three critical hub genes, CCR5, COL1A1 and CXCR3, were significantly associated with prostate cancer prognosis. CONCLUSION: Our findings revealed the pattern of immune cell infiltration in mCRPC, and identified the types and genes of immune cells correlated with clinical outcomes. A new theoretical basis for immunotherapy may be given by our results.
引用
收藏
页码:363 / 377
页数:15
相关论文
共 50 条
  • [41] The changing landscape in metastatic castration-resistant prostate cancer
    Leibowitz-Amit, Raya
    Joshua, Anthony M.
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2013, 7 (03) : 243 - 248
  • [42] Talazoparib for the Treatment of Metastatic Castration-resistant Prostate Cancer
    Qureshi, Zaheer
    Fatima, Eeshal
    Safi, Adnan
    Khanzada, Mikail
    Altaf, Faryal
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (04): : 206 - 214
  • [43] New treatment options for patients with metastatic castration-resistant prostate cancer
    Higano, Celestia S.
    CANCER TREATMENT REVIEWS, 2012, 38 (05) : 340 - 345
  • [44] Comparison of metastatic castration-resistant prostate cancer in bone with other sites: clinical characteristics, molecular features and immune status
    Xu, Zhengquan
    Ding, Yanhong
    Lu, Wei
    Zhang, Ke
    Wang, Fei
    Ding, Guanxiong
    Wang, Jianqing
    PEERJ, 2021, 9
  • [45] Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer
    Moreira, D. M.
    Howard, L. E.
    Sourbeer, K. N.
    Amarasekara, H. S.
    Chow, L. C.
    Cockrell, D. C.
    Hanyok, B. T.
    Pratson, C. L.
    Aronson, W. J.
    Kane, C. J.
    Terris, M. K.
    Amling, C. L.
    Cooperberg, M. R.
    Liede, A.
    Freedland, S. J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2015, 18 (04) : 333 - 337
  • [46] Management of metastatic castration-resistant prostate cancer after first-line docetaxel
    Harrington, J. A.
    Jones, R. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (14) : 2133 - 2142
  • [47] CCNB1 and AURKA are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine
    Chen, Xi
    Ma, Junjie
    Wang, Xin'an
    Zi, Tong
    Qian, Duocheng
    Li, Chao
    Xu, Chengdang
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [48] Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
    Mulders, Peter F.
    De Santis, Maria
    Powles, Thomas
    Fizazi, Karim
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (06) : 655 - 663
  • [49] The efficacy and safety of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis
    Wang, Xing-Hui
    Wang, Zhi-Qiang
    Mu, Zhen-Yu
    Zhu, Li-Ping
    Zhong, Chong-Fu
    Guo, Shanchun
    MEDICINE, 2022, 101 (31) : E29715
  • [50] A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates
    Caroline Jochems
    Jo A. Tucker
    Kwong-Yok Tsang
    Ravi A. Madan
    William L. Dahut
    David J. Liewehr
    Seth M. Steinberg
    James L. Gulley
    Jeffrey Schlom
    Cancer Immunology, Immunotherapy, 2014, 63 : 407 - 418